Page 126 - Read Online

Page 18 of 19 Kornberg et al. Hepatoma Res 2018;4:60 I http://dx.doi.org/10.20517/2394-5079.2018.86

115. Goldaracena N, Barbas AS, Selzner M. Normothermic and subnormothermic ex-vivo liver perfusion in liver transplantation. Curr Opin
Organ Transplant 2016;21:315-21.
116. Allard MA, Castro-Benitez C, Imai K, Selten J, Lopez A, Sebagh M, Lemoine A, Sa Cunha A, Cherqui D, Castaing D, Vibert E, Adam R.
Suitability of livers for transplantation when treated by normothermic machine perfusion. Clin Transplant 2018;32:e13256.
117. Quillin RC, Guarrera JV. Hypothermic machine perfusion in liver transplantation. Liver Transpl 2018;24:276-81.
118. He X, Guo Z, Zhao Q, Ju W, Wang D, Wu L, Yang L, Ji F, Tang Y, Zhang Z, Huang S, Wang L, Zhu Z, Liu K, Zhu Y, Gao Y, Xiong W,
Han M, Liao B, Chen M, Ma Y, Zhu X, Huang W, Cai C, Guan X, Li XC, Huang J. The first case of ischemia-free organ transplantation in
humans: a proof of concept. Am J Transplant 2018;18:737-44.
119. Amisaki M, Saito H, Tokuyasu N, Sakamoto T, Honjo S, Fujiwara Y. Prognostic value of postoperative complication for early recurrence
after curative resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2018;17:323-9.
120. Pravisani R, Baccarani U, Isola M, Adani G, Lorenzin D, Terrosu G, Risaliti A. Impact of surgical complications on the risk of
hepatocellular carcinoma recurrence after hepatic resection. Updates Surg 2018;70:57-66.
121. Khandoga A, Drefs M, Schoenberg M, Schiergens T, Frenes K, Op den Winkel M, Trumm C, Angele MK, Guba M, Werner J, Rentsch M.
Differential significance of early surgical complications for acute and long-term recurrence-free survival following surgical resection of
hepatocellular carcinoma: do comorbidities play a role? Eur J Gastroenterol Hepatol 2017;29:1045-53.
122. Dai WC, Chok KSH, Sin SL, Chan ACY, Cheung TT, Wong TCL, Lo CM. Impact of intraoperative blood transfusion on long-term
outcomes of liver transplantation for hepatocellular carcinoma. ANZ J Surg 2018;88:E418-23.
123. Elsabbagh AM, Girlanda R, Hawksworth J, Pichert MD, Williams C, Pozzi A, Kroemer A, Nookala A, Smith C, Matsumoto CS, Fishbein
TM. Impact of early reoperation on graft survival after liver transplantation: univariate and multivariate analysis. Clin Transplant
2018;32:e13228.
124. Pandey CK, Singh A, Kajal K, Dhankhar M, Tandon M, Pandey VK, Karna ST. Intraoperative blood loss in orthotopic liver transplantation:
the predictive factors. World J Gastrointest Surg 2015;7:86-93.
125. Teng F, Wang GH, Tao YF, Guo WY, Wang ZX, Ding GS, Shi XM, Fu ZR. Criteria-specific long-term survival prediction model for
hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol 2014;20:10900-7.
126. Liu B, Teng F, Fu H, Guo WY, Shi XM, Ni ZJ, Gao XG, Ma J, Fu ZR, Ding GS. Excessive intraoperative blood loss independently predicts
recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol 2015;15:138.
127. Kornberg A, Witt U, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Prognostic impact of intraoperative blood loss in liver
transplant patients with advanced hepatocellular carcinoma. Anticancer Res 2016;36:5355-64.
128. You DD, Kim DG, Seo CH, Choi HJ, Yoo YK, Park YG. Prognostic factors after curative resection hepatocellular carcinoma and the
surgeon’s role. Ann Surg Treat Res 2017;93:252-9.
129. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D’Angelica MI, Blumgart LH, Dematteo RP. Operative blood loss
independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 2009;249:617-23.
130. Elemary M, Seghatchian J, Stakiw J, Bosch M, Sabry W, Goubran H. Transfusion challenges in hematology oncology and hematopoietic
stem cell transplant - literature review and local experience. Transfus Apher Sci 2017;56:317-21.
131. Iqbal N, Haider K, Sundaram V, Radosevic J, Burnouf T, Seghatchian J, Goubran H. Red blood cell transfusion and outcome in cancer.
Transfus Apher Sci 2017;56:287-90.
132. Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, Zhou Y, Zhou Y, Zhang Y. Perioperative allogenenic blood transfusion is associated with
worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One 2013;8:e64261.
133. Seehofer D, Öllinger R, Denecke T, Schmelzle M, Andreoua A, Schott E, Pratschke J. Blood transfusions and tumor biopsy may increase
HCC recurrence rates after liver transplantation. J Transplant 2017; doi: org/10.1155/2017/9731095.
134. Han S, Kim G, Ko JS, Sinn DH, Yang JD, Joh JW, Lee SK, Gwak MS. Safety of the use of blood salvage and autotransfusion during liver
transplantation for hepatocellular carcinoma. Ann Surg 2016;264:339-43.
135. Zhai B, Sun XY. Controversy over the use of intraoperative blood salvage autotransfusion during liver transplantation for hepatocellular
carcinoma patients. World J. Gastroenterol 2013;19:3371-4.
136. Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of
immunosuppression? Transl Gastroenterol Hepatol 2017;2:80.
137. Khorsandi SE, Heaton N. Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. Transl
Gastroenterol Hepatol 2016;1:25.
138. Suthanthiran M, Hojo M, Maluccio M, Boffa DJ, Luan FL. Post-transplantation malignancy: a cell autonomous mechanism with
implications for therapy. Trans Am Clin Climatol Assoc 2009;120:369-88.
139. Zhu H, Sun Q, Tan C, Xu M, Dai Z, Wang Z, Fan J, Zhou J. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF 1α
expression in vivo. Mol Med Rep 2014;10:585-92.
140. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD. Analysis of risk factors for tumor recurrence after
liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005;11:497-503.
141. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular
carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008;248:857-62.
142. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O’Beirne J, Poyato-González A, Ferrín-Sánchez G,
Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after
liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013;59:1193-9.
143. Zaza G, Granata S, Caletti C, Signorini L, Stallone G, Lupo A. mTOR inhibition role in cellular mechanisms. Transplantation 2018;102:S3-
16.
144. de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation 2017;101:45-55.
145. Duvoux C, Toso C. mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation? Transplant Rev (Orlando)